Followers | 179 |
Posts | 24830 |
Boards Moderated | 17 |
Alias Born | 04/03/2002 |
Thursday, August 19, 2021 1:13:53 PM
Eric Richman, Chief Executive Officer of Gain, added, “We are pleased with the progress in advancing our preclinical compounds to the clinic and announced important and compelling data related to our GBA Parkinson’s program. Our SEE-Tx supercomputing platform technology designed to identify novel allosteric binding sites on misfolded proteins continues to meet objectives within our internal pipeline and our external pharmaceutical partnerships. We continue to advance our pipeline towards achieving our mission in redefining drug discovery and developing novel therapies for devastating conditions with significant unmet medical need.”
Recent GANX News
- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 • GlobeNewswire Inc. • 06/28/2024 08:39:04 PM
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO • GlobeNewswire Inc. • 06/27/2024 08:08:08 PM
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease • GlobeNewswire Inc. • 06/27/2024 12:35:48 PM
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/25/2024 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 12:30:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:40:23 PM
- Gain Therapeutics Announces Pricing of $11.0 Million Public Offering • GlobeNewswire Inc. • 06/14/2024 01:00:59 AM
- Gain Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 06/13/2024 08:44:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 08:38:54 PM
- Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:03:12 PM
- Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 04/24/2024 01:25:00 PM
- Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer • GlobeNewswire Inc. • 04/08/2024 01:25:00 PM
- Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 04/01/2024 01:25:00 PM
- Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Gain Therapeutics to Present at Public Ventures Discovery Day • GlobeNewswire Inc. • 03/15/2024 06:30:11 PM
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease • GlobeNewswire Inc. • 02/27/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:17 PM
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight • GlobeNewswire Inc. • 02/14/2024 05:29:34 PM
- UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 02:56:04 PM
- Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:26:33 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM